Sutro Biopharma, Inc. (STRO) company profile

The company is a clinical-stage oncology biotechnology enterprise dedicated to the design and development of novel-format and site-specific antibody-drug conjugates (ADCs) to treat solid tumors. Leveraging proprietary cell-free protein synthesis and site-specific conjugation platforms, known as XpressCF and XpressCF+, the organization creates homogeneous therapeutics, including standard ADCs, immunostimulatory ADCs, and dual-payload ADCs. Its clinical pipeline is led by STRO-004, an investigational therapy targeting tissue factor in patients with advanced solid tumors, alongside preclinical candidates STRO-227 and STRO-006. In addition to internal development, the firm partners with pharmaceutical and biotechnology companies through research, development, and licensing collaborations across oncology and infectious disease vaccine applications.

The business operates as a clinical-stage development firm conducting multicenter clinical trials in medical facilities. Its corporate relationships and collaboration partners extend across the United States, Europe, and Asia, including agreements covering the Greater China territory. The provided report does not specify a corporate headquarters location.

Summary of the business section of Sutro Biopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 137 full-time employees.”